Aducanumab (Biogen Trial)
Aducanumab was a compound that was being tested by Biogen as a possible therapy for Alzheimer's. This drug works by binding to beta-amyloid to reduce the amount of beta-amyloid in the brain. In March of 2019, an analysis suggested there was no benefit, so trials were stopped. However, in October, at the annual Clinical Trials for Alzheimer's Disease (CTAD) conference, results from another analysis was presented where patients received a higher dosage. Given this analysis, Biogen reversed its stance and reported statistically significant improvement in some participants. The drug will continue clinical trials in 2020.